Generic Medicine Info
Indications and Dosage
Acute bronchospasm
Adult: As sulfate: Metered-dose inhaler releasing 750 mcg per inhalation: 1 or 2 inhalations; repeat if necessary. Max: Up to 12 inhalations in 24 hr. As 5% soln from a hand nebuliser: 10 inhalations. With a nebulising device e.g. intermittent positive-pressure breathing (IPPB) apparatus: 0.2-0.3 ml of a 5% solution diluted up to 2.5 ml physiological saline, administered not more often than every 4 hr.
Child: As sulfate: Metered-dose inhaler: >12 yr: 1 or 2 inhalations (750 mcg); repeat if necessary after not <3 hr. Max in 24 hr: <6 yr: Up to 4 inhalations; 6-12 yr: Up to 8 inhalations; >12 yr: Up to 12 inhalations. Nebuliser: Infants and children: 0.01-0.02 ml of 5% solution; min dose: 0.1 ml; max dose: 0.3 ml diluted in 2-3 ml normal saline every 4-6 hr or more frequently if necessary.

Adult: As sulfate: 250-500 mcg by slow IV inj.

Chronic management of reversible airways obstruction
Adult: As sulfate: 20 mg 3 or 4 times daily.
Child: As sulfate: Up to 1 yr: 5-10 mg tid; 1-3 yr: 5-10 mg 4 times daily; 3-12 yr: 40-60 mg daily in divided doses.

Adult: As sulfate: Up to 240 mg daily in divided doses.
May be taken with or without food.
Cardiac arrhythmias associated with tachycardia.
Special Precautions
CV disease (e.g. arrhythmia, hypertension, CHF), DM, glaucoma, hyperthyroidism, hypokalaemia, seizure disorders. Pregnancy and lactation.
Adverse Reactions
Tachycardia, nervousness, increased serum glucose, increased potassium levels, tremor, palpitation, headache, dizziness, insomnia, nausea, vomiting, bad taste, heartburn, xerostomia, trembling, muscle cramps, weakness, coughing, pharyngitis, increased diaphoresis, paradoxical bronchospasm, hypertension, chest pain, angina, drowsiness, diarrhoea, taste change.
Inhalation/Respiratory/PO: C
Symptoms: Tachycardia, tremor, hypertension, angina, seizures, hypokalaemia. Treatment: Immediate discontinuation and symptomatic and supportive therapies. Cautious use of β-blockers may be considered in severe cases.
Drug Interactions
Effects may be antagonised by β-blockers e.g. propranolol. Duration of bronchodilation may be increased with inhaled ipratropium. Increased adverse effects with MAOIs, TCAs, sympathomimetics.
Potentially Fatal: Increased risk of malignant arrhythmias with halothane.
Description: Orciprenaline is a direct acting sympathomimetic with predominantly β2-adrenoceptor stimulant activity. It has minimal effect on heart rate.
Onset: Inhaler: Within 1 min. Nebuliser: 5-30 min. Oral: 15 min.
Duration: Up to 6 hr (inhalation).
Absorption: Absorbed from the GI tract (oral).
Metabolism: Hepatic; undergoes extensive first-pass metabolism.
Excretion: Via urine (mainly as metabolites).
Metered-dose inhaler: Store at 15-25°C. Nebuliser: Store below 25°C. Protect from light.
Store in tight, light-resistant containers at 15-30°C.
Disclaimer: This information is independently developed by MIMS based on Orciprenaline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in